Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For...

Published on 13 Nov 2024 on Benzinga · via Yahoo Finance

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment,...

Read the rest of the article

Start tracking your investments with Statfolio

It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent...

Simply Wall St. · via Yahoo Finance 6 Dec 2024

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In t...

Insider Monkey · via Yahoo Finance 23 Nov 2024

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024...

Insider Monkey · via Yahoo Finance 19 Nov 2024

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we ...

Insider Monkey · via Yahoo Finance 19 Nov 2024

HP Investors are enthralled with artificial intelligence. Making printers and selling the ink to ...

GuruFocus.com · via Yahoo Finance 18 Nov 2024

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment,...

Benzinga · via Yahoo Finance 13 Nov 2024

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarte...

Insider Monkey · via Yahoo Finance 1 Nov 2024

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of...

Benzinga · via Yahoo Finance 31 Oct 2024

, opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose vers...

Reuters 31 Oct 2024

Research and development expenses reflect a commitment to innovation, with a significant increase...

GuruFocus.com · via Yahoo Finance 31 Oct 2024